Yukon Immunization Program Manual

Section 8 — Biological Products

Rotavirus Vaccine

June 2026

Table of Contents

<table>
<tr><th colspan="4">Rotavirus Vaccine — RotaTeq®</th></tr>
<tr><td>Manufacturer</td><td>Merck Canada Inc.</td><td>Biological Classification</td><td>Live attenuated viral vaccine</td></tr>
<tr><td>Current Formulation</td><td colspan="3"></td></tr>
<tr><td rowspan="2">INDICATIONS</td><td colspan="3">SCHEDULE</td></tr>
<tr><td colspan="2">1. Routine Schedule for Healthy Infants 6 weeks to before 8 months of age</td><td>• 1st Dose: 2.0 mL orally at 2 months
• 2nd Dose: 2.0 mL orally at 4 months
• 3rd Dose: 2.0 mL orally at 6 months</td></tr>
<tr><td>MINIMUM INTERVAL</td><td colspan="3">• Minimum interval: 4 weeks between doses
• Minimum age:
  ○ First dose must be given before 15 weeks of age
  ○ All doses must be completed before 8 months of age</td></tr>
<tr><td>AVAILABLE FORMAT</td><td colspan="3">Single-dose 2.0 mL oral dosing tube</td></tr>
<tr><td>CONTRAINDICATIONS</td><td colspan="3">• History of anaphylaxis after a previous dose or any component of rotavirus vaccine
• History of intussusception
• Known or suspected Severe Combined Immunodeficiency Disease, also known as SCID
• Known or suspected immunocompromising condition, unless vaccination is recommended in consultation with a physician specialist or expert in the condition.
• Uncorrected congenital gastrointestinal condition that may predispose to intussusception, such as Meckel’s diverticulum</td></tr>
</table>

Rotavirus Vaccine	RotaTeq®
PRECAUTIONS & SPECIAL CONSIDERATIONS	• **Acute gastroenteritis:** Infants with moderate to severe gastroenteritis should have rotavirus vaccine deferred until symptoms improve, unless deferral would result in the first dose being given at 15 weeks of age or older. Infants with mild gastroenteritis can be vaccinated. • **Chronic gastrointestinal conditions:** The safety and efficacy of rotavirus vaccine have not been established in infants with pre-existing chronic gastrointestinal disease. However, infants with chronic gastrointestinal disease who are not immunocompromised are likely to benefit from vaccination and may be vaccinated. • **Preterm infants:** Healthy preterm infants may be vaccinated beginning at 6 weeks chronological age. First dose must be given before 15 weeks of age and the series completed 8 months before. • **Previous rotavirus infection:** Infants who had rotavirus gastroenteritis before completing the vaccine series should still start or complete the series, as natural infection may only provide partial immunity. • **Immunocompromised household contacts:** Vaccine virus shedding may occur after vaccination, particularly after the first dose. Emphasize careful hand hygiene after diaper changes, especially when there are immunocompromised household contacts. • **Schedule errors:** If the first dose is inadvertently given at 15 weeks of age or older, complete the series using a minimum interval of 4 weeks between doses and complete before 8 months of age. • **Family history of congenital/hereditary immunodeficiency:** Consider assessment of immune competence before vaccination if immunodeficiency is suspected.
PREGNANCY AND LACTATION	• Infants living with pregnant individuals can be vaccinated. • Breastfed infants can receive rotavirus vaccine.
INTERCHANGEABILITY	Whenever possible, complete the series with the same rotavirus vaccine product. If the product used for a previous dose is unknown or unavailable, complete the series with the available product. If any dose in the series was RotaTeq®, a total of 3 doses of rotavirus vaccine should be administered.

Rotavirus Vaccine	RotaTeq®
RECONSTITUTION AND DILUTION	• No reconstitution or dilution required. • Administer directly from the oral dosing tube.
ADMINISTRATION	• Oral administration only. Do not inject. • Give the entire contents of the oral dosing tube. • Administer toward the inside of the infant's cheek until the tube is empty. • If the infant spits out or regurgitates part or all of the dose, do not administer a replacement dose. Continue the series as scheduled. • There are no restrictions on food, liquid, or breastfeeding before or after rotavirus vaccination.
CONCURRENT ADMINISTRATION WITH OTHER VACCINES	Rotavirus vaccine may be given at the same time as, or at any time before or after, other live or non-live vaccines.
SEROLOGICAL TESTING	Serological testing is not recommended before or after rotavirus immunization.
VACCINE COMPONENTS	**Active Ingredients** • Live attenuated human-bovine rotavirus reassortants (G1, G2, G3, G4, and P1A[8]) **Non-Medicinal Ingredients** • Sucrose • Sodium citrate • Sodium phosphate • Sodium hydroxide • Polysorbate 80 • Cell culture media **Additional Information** • No preservatives • No thimerosal
APPEARANCE	Pale yellow liquid that may have a pink tint.

Rotavirus Vaccine	**RotaTeq®**
BLOOD/ BLOOD PRODUCTS	Does not contain human blood or blood products.
BOVINE/ PORCINE PRODUCTS	• RotaTeq® contains fetal bovine serum • Porcine circovirus types 1 and 2 DNA fragments have been detected in RotaTeq® and are not known to cause disease in humans.
LATEX	Latex free

EXPECTED REACTIONS	• **Systemic:** Diarrhea, vomiting, irritability, abdominal pain, flatulence, dermatitis
	• **Serious adverse events are rare:**
	  ○ Intussusception:
	  ▪ There is a small increased risk of intussusception following rotavirus vaccine, estimated at 1 to 7 excess cases per 100,000 doses in the 7 days following the first and second doses.
	  ▪ Parents and caregivers should be advised to seek medical care if the infant develops signs or symptoms of intussusception, such as severe crying, repeated vomiting, blood in the stool, weakness, or episodes of drawing the knees to the chest
	  ▪ Report intussusception occurring within 21 days following any dose to YIP.

STORAGE AND HANDLING	• Store at +2°C to +8°C • Do not freeze • Protect from light
REFERENCES AND RESOURCES	
National Advisory Committee on Immunization Statements Canadian Immunization Guide Product Monograph	